학술논문
A Phase I Trial of Activated Donor-Derived Marrow Infiltrating Lymphocytes to Treat Relapsed Hematologic Malignancies after Allogeneic Transplantation with Post-Transplantation Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis
Document Type
Article
Author
Rimando, Joseph; Mazziotta, Francesco; Gareau, Alison; Bettinotti, Maria; Webster, Jonathan Allen; Ali, Syed Abbas; Imus, Philip; Lemas, Mario Victor; DeZern, Amy E.; Levis, Mark J.; Zahurak, Marianna; Varadhan, Ravi; Ambinder, Richard F.; Huff, Carol; Gojo, Ivana; Jones, Richard J.; Borrello, Ivan M.; Luznik, Leo
Source
Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p3473-3473, 1p
Subject
Language
ISSN
00064971; 15280020
Abstract
Background:Donor lymphocyte infusion (DLI) or a second allogeneic transplant (HCT) are the only curative treatments for hematologic malignancies relapsing after initial HCT. Both approaches lack significant efficacy and may cause considerable toxicity. Post-transplant cyclophosphamide (PTCy) used as graft-versus-host disease (GVHD) prophylaxis eliminates alloreactive T cells and enriches for tumor-specific T cells in the bone marrow. We hypothesized that expanded, donor-derived marrow infiltrating lymphocytes (alloMILs) collected post-HCT could restore antitumor immunity in relapsed recipients without the additional GVHD and toxicity seen with DLI or second HCT.